Grifols (NASDAQ:GRFS) Sets New 12-Month Low – Should You Sell?

Grifols, S.A. (NASDAQ:GRFS) shares reached a new 52-week low during mid-day trading on Monday . The company traded as low as $7.26 and last traded at $7.2870, with a volume of 409443 shares traded. The stock had previously closed at $7.40.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on GRFS. Wall Street Zen downgraded shares of Grifols from a “buy” rating to a “hold” rating in a research report on Monday, May 18th. Zacks Research lowered Grifols from a “hold” rating to a “strong sell” rating in a report on Friday, May 8th. Finally, Weiss Ratings upgraded Grifols from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Three analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $10.00.

Grifols Stock Down 1.7%

The company has a market cap of $4.95 billion, a PE ratio of 38.29, a P/E/G ratio of 0.29 and a beta of 0.65. The business has a 50-day simple moving average of $7.93 and a 200-day simple moving average of $8.52. The company has a quick ratio of 0.85, a current ratio of 2.47 and a debt-to-equity ratio of 1.16.

Grifols (NASDAQ:GRFS) last announced its earnings results on Saturday, February 14th. The biotechnology company reported $0.38 earnings per share for the quarter. The business had revenue of $2.32 billion during the quarter. Grifols had a return on equity of 6.21% and a net margin of 5.54%. Equities research analysts anticipate that Grifols, S.A. will post 1.06 EPS for the current year.

Institutional Trading of Grifols

Large investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC grew its holdings in shares of Grifols by 71.6% during the first quarter. EverSource Wealth Advisors LLC now owns 14,685 shares of the biotechnology company’s stock worth $118,000 after buying an additional 6,127 shares in the last quarter. Royal Bank of Canada boosted its position in Grifols by 15.4% during the first quarter. Royal Bank of Canada now owns 785,703 shares of the biotechnology company’s stock worth $6,301,000 after acquiring an additional 104,850 shares during the last quarter. Quantinno Capital Management LP raised its holdings in Grifols by 42.0% in the 1st quarter. Quantinno Capital Management LP now owns 352,798 shares of the biotechnology company’s stock valued at $2,829,000 after acquiring an additional 104,418 shares during the last quarter. Flat Footed LLC grew its position in shares of Grifols by 26.5% in the first quarter. Flat Footed LLC now owns 1,372,394 shares of the biotechnology company’s stock valued at $11,007,000 after purchasing an additional 287,867 shares in the last quarter. Finally, Cetera Investment Advisers grew its position in shares of Grifols by 11.0% in the first quarter. Cetera Investment Advisers now owns 49,633 shares of the biotechnology company’s stock valued at $398,000 after purchasing an additional 4,932 shares in the last quarter.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.